Abbonarsi

sIL-2R levels predict the spontaneous remission in sarcoidosis - 09/09/20

Doi : 10.1016/j.rmed.2020.106115 
Ying Zhou a, 1, Yuan Zhang b, 1, Mengmeng Zhao b, 1, Qiuhong Li b, 1, Huiping Li b,
a Department of Respiratory Medicine and Clinical Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China 
b Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China 

Corresponding author. Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Shanghai, 200433, China.Department of Respiratory MedicineShanghai Pulmonary HospitalTongji University School of Medicine507 Zhengmin RoadShanghai200433China

Abstract

Background

Sarcoidosis is associated with a wide range of disease outcomes including spontaneous remission and progressive courses. It is necessary to identify patients with spontaneous remission without corticosteroid treatment. This study aimed to identify the markers for predicting spontaneous remission in patients with sarcoidosis.

Methods

453 patients diagnosed with sarcoidosis at the Shanghai Pulmonary Hospital between Jan 2013 and Aug 2017 and were followed-up for more than 2 years were enrolled. Patients were divided into spontaneous remission group and non-remission group. Differences of variables between groups were analyzed by chi-square test or unpaired Student's t-test. The cumulative spontaneous remission rate was analyzed using the Kaplan-Meier method.

Results

Of the 173 patients (stage I/II/III/IV, 53/110/6/4) without medication, 117 (67.6%) achieved spontaneous remission. The serum level of soluble interleukin-2 (IL-2) receptor (sIL-2R) and the ratio of CD4/CD8 was significantly lower and CD8+ T cell was significantly higher in spontaneous remission group when compared with non-remission group (P < 0.001, P = 0.042 and P = 0.048). Multivariate logistic regression model showed sIL-2R level was an independent predictor of spontaneous remission (P = 0.021). In stage I subgroup, a cut-off value of 1129.5U/ml was obtained from the ROC curve, which yielded a sensitivity of 50% and a specificity of 94.4%. In stage II subgroup, a cut-off value of 1026.5U/ml was obtained with a sensitivity of 66.7% and a specificity of 68.7%.

Conclusion

This study provided useful information that sIL-2R level could be used as a maker for spontaneous remission in determining the treatment strategies for patients with pulmonary sarcoidosis.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

It is important to identify patients with spontaneous remission in sarcoidosis.
sIL-2R level was an independent predictor of spontaneous remission in sarcoidosis.
CD8+ T cell and CD4/CD8 should be studied in larger populations to assess the prognostic roles.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Sarcoidosis, Soluble interleukin-2 receptor, Spontaneous remission, Chest radiograph stage


Mappa


© 2020  Elsevier Ltd. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 171

Articolo 106115- settembre 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • The S100 calcium-binding protein A4 level is elevated in the lungs of patients with idiopathic pulmonary fibrosis
  • Jong-Uk Lee, Hun Soo Chang, Eun-Young Shim, Jai-Seong Park, Eun-Suk Koh, Hwa-Kyun Shin, Jong-Sook Park, Choon-Sik Park
| Articolo seguente Articolo seguente
  • Patient characteristics associated with adherence to pulmonary nodule guidelines
  • Jonathan M. Iaccarino, Katrina Steiling, Christopher G. Slatore, Mari-Lynn Drainoni, Renda Soylemez Wiener

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.